Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical sector.
Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 21 August 2020.
Making headlines this time are two targeted acquisitions by big pharma, negative US FDA decisions and the outlook for the COVID-19-related business.
Stories mentioned in this episode:
(Also see "J&J Seeks Command Position In FcRn Space With Momenta Buyout" - Scrip, 19 Aug, 2020.)
(Also see "Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn" - Scrip, 17 Aug, 2020.)
(Also see "Not Such A Sure Thing: FDA Knocks Back BioMarin’s Roctavian" - Scrip, 19 Aug, 2020.)
(Also see "Gilead’s RA Hopeful Filgotinib Hit By Complete Response Letter" - Scrip, 19 Aug, 2020.)
(Also see "Can Moderna Meet Its COVID Vaccine Expectations?" - Scrip, 17 Aug, 2020.)